# BXCL501 for Agitation in Schizophrenia

> **NCT03708315** · PHASE1 · COMPLETED · sponsor: **Yale University** · enrollment: 11 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Dexmedetomidine Hydrochloride
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03708315
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-09
- **Primary completion:** 2023-05-26
- **Final completion:** 2023-05-26
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03708315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03708315, "BXCL501 for Agitation in Schizophrenia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03708315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*